ArticleAnnals of coloproctology2026

Effectiveness of primary tumor resection for survival after first-line cetuximab or bevacizumab in KRAS wild-type metastatic colorectal cancer treated with subsequent trifluridine/tipiracil or regorafenib.

Yu-Hsun Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.